Plain-English translation of NCT07318051 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Breast Cancer research guide →Researchers at Natera are testing a blood test called a molecular residual disease (MRD) assay to see if it can detect tiny amounts of cancer DNA left in the bloodstream after surgery or other cancer treatment. This test may help doctors know whether cancer is likely to come back. The study will follow people with many different types of solid tumors over several years.
After cancer treatment, doctors have limited ways to know early on if cancer might return. This new blood test could give doctors an earlier warning sign by finding cancer DNA in the blood, potentially allowing for faster intervention before cancer grows back.
You likely qualify if…
You likely don't qualify if…
You will have blood drawn approximately every six weeks for up to two years after your surgery or completion of primary treatment. Leftover tissue from your standard cancer care will also be collected for testing. After the first two years, you'll have follow-up visits at one and five years to check on your status, and researchers may follow you for up to eight years total. Importantly, you will not receive individual test results from this study—the blood tests are for research purposes only.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
United States
Sponsor
Natera, Inc.
Enrollment target
~9,600 participants
Started
July 2025
Primary completion
January 2035
Age range
18 Years and older
Last updated on clinicaltrials.gov in January 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
SCORE Study team
Natera, Inc.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.